• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

Maricann Group Files Third Quarter Financial Results

December 1, 2017

 (Photo Credit - Nick Youngson)

 

TORONTO, ONTARIO--(Marketwired - Dec. 1, 2017) - Maricann Group Inc. (CSE:MARI) (OTC:MRRCF) (FRANKFURT:75M) ("Maricann" or the "Company") filed its financial statements for the 3 months ending September 30, 2017, with results that were consistent with our expectations. Revenue is expected to increase in the first quarter of 2018 when the Company's joint pharmacy initiative is expected to launch. Product distribution for this initiative will occur through previously announced exclusive and primary supplier relationships with retail pharmacies (see press releases dated November 6, 2017 and November 13, 2017). Inventory has been reserved for this initiative to ensure patient supply. Maricann will supply medicinal cannabis products directly to pharmacy patients, following their receipt of a prescription from a physician and expert education by patients' local pharmacists. Further inventory has been reserved for export to European markets that the Company expects to be permitted following a successful Good Manufacturing Practice (GMP) certification of the Company's Langton, Ontario operations. Inspection by European authorities for the designation is anticipated to be complete by mid-December 2017 with the results to be provided shortly thereafter.

 

Germany - Continued Progress

Tender Bid Submission

 

Maricann's joint venture partner has submitted bid documents for the German government's tender process for regulated cannabis, following qualification in the first round of such process as one of 10 successful applicants to move forward (of 118 applicants in total). The tender process has been delayed multiple times due to ongoing legal proceedings related to unsuccessful submissions by other applicants in the initial qualifying round. A further delay in the tender process may occur due to ongoing legal proceedings, however, a final decision may be forthcoming as early as March of 2018.

 

Export to Germany

 

Maricann's Canadian facilities will undergo inspection for GMP Certification in December 2017 as referenced above. This certification, if received, will permit Maricann to export dry cannabis flower to Germany and other markets. It is expected that Maricann will be permitted to export cannabis products to Germany in the first quarter of 2018, subject to receipt of the required approvals.

 

Narcotics and Wholesale Licence

 

Maricann GmbH has applied for a narcotics licence and wholesale narcotics licence in Germany. If received, these licenses will allow Maricann to import its own cannabis products directly from Canada and distribute them to pharmaceutical distributors and pharmacies directly, helping to preserve the Company's profit margin. This import and wholesale activity is separate and distinct from the tender process referenced above. Key personnel have been hired, including Dr. Thomas Klumpp PhD Pharmacy, as Qualified Person. Dr. Klumpp's previous experience as Head of Production Supply at Bayer (Bitterfeld) and Manager of CC Production in Africa, Asia, Australia for Bayer Corp. (Leverkusen) has positioned Dr. Klumpp as an expert in all areas of Good Manufacturing Practices in Pharmaceutical Production as he is an expert pharmacist and specialist in pharmaceutical technology.

 

Maricann forms Registered Agricultural Subsidiary for CBD Production and Distribution in Europe

 

MariPlant GmbH has been registered as a 95% owned subsidiary in Germany. MariPlant has registered formally as a "Landwirtschaftliches Unternehmen" (Agricultural Company), with 5% owned by General Manager of Maricann GmbH, Josef Spaeth, a registered "Landwirtschaft" (Farmer). MariPlant will cultivate approved industrial hemp cultivars and extract CBD to be used in its "Mariplant" products. It is expected that these CBD products will be distributed through MariPlant's own online shop in Europe, starting in February of 2018 and it is further anticipated that MariPlant will distribute 25mg CBD metered dose softgel capsules with VesiSorb delivery technology as its first product offering.

 

About Maricann

 

Maricann, which has federal licenses in Canada to cultivate, extract, formulate and distribute cannabis, is rapidly expanding its Canadian production, based in Norfolk County, Ontario, adding 22,245 kg of annual production of dry flower to come online in Q2 2018, with additional production planned. Maricann is focused on expanding capacity in a truly differentiated product offering, in support of its previously announced joint pharmacy initiative and future global export opportunities.

 

For more information about Maricann, please visit our website at www.maricann.com

 

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR OTC MARKETS GROUP INC., NOR THEIR REGULATIONS SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

 

Forward Looking Information

 

Certain statements in this document contain forward-looking statements which can be identified by the use of forward-looking terminology such as "believes", "expects", "may", "desires", "will", "should", "projects", "estimates", "contemplates", "anticipates", "intends", or any negative such as "does not believe" or other variations thereof or comparable terminology. No assurance can be given that potential future results or circumstances described in the forward-looking statements will be achieved or will occur. By their nature, these forward-looking statements, necessarily involve risks and uncertainties, including those discussed herein, that could cause actual results to significantly differ from those contemplated by these forward-looking statements. Such statements reflect the view of the Company with respect to future events, and are based on information currently available to the Company and on assumptions, which it considers reasonable. The forward looking statements in this release include statements regarding the planned increase in annual production and the implementation, the anticipated increase in revenue in the first quarter of 2018, the launch of the Company's joint pharmacy initiative, the export to European markets and a successful Good Manufacturing Practice (GMP) certification of the Company's Langton, Ontario operations, the timing of the German tender bid process, the timing and ability to export to the German market from Canada and the rollout of MariPlant's product offerings. Management cautions readers that the assumptions relative to the future events, several of which are beyond Management's control, could prove to be incorrect, given that they are subject to certain risk and uncertainties, and that actual results may differ materially from those projected. Factors which could cause results or events to differ from current expectations include, among other things: fluctuations in operating results; the impact of general economic, industry and market conditions; the ability to recruit and retain qualified employees; fluctuations in cash flow; failure to obtain required financing; increased levels of outstanding debt and obligations under a capital lease; expectations regarding market demand for particular products and the dependence on new product development; the impact of market change; and the impact of price and product competition. Management disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. The reader is cautioned not to place undue reliance on forward-looking information.

Please reload

LATEST NEWS
Please reload

Please reload

DMO

© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.